Products for Research Use Only
RegisterLogin

Samotolisib

CAT: 0804-HY-12513-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12513-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits mTORC1/2 at low nanomolar concentrations[1][2].
CAS Number
1386874-06-1
Product Name Alternative
LY3023414
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Autophagy; DNA-PK; mTOR; PI3K
Type
Reference compound
Related Pathways
Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LY3023414.html
Purity
99.27
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(N1C[C@@H](OC)C)N(C)C2=C1C3=CC(C4=CC(C(C)(O)C)=CN=C4)=CC=C3N=C2
Molecular Formula
C23H26N4O3
Molecular Weight
406.48
Precautions
H315, H319, H320
References & Citations
[1]Wei L, et al. Genomic profiling is predictive of response to CDDP treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget. 2016 Nov 22;7 (47) :76374-76389.|[2]Smith MC, et al. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth. Mol Cancer Ther. 2016 Oct;15 (10) :2344-2356
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
MTOR; mTORC1; mTORC2; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ

Alternative Products

CatalogName
GTR19167989-01Samotolisib
C13343-5mgSamotolisib (LY3023414)

Popular Products